• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    Transporting Treatment: An Examination of Tubing Technologies

    Outward Appearance: Reviewing Surface Treatment Options

    Face to (Virtual) Face: Telemedicine Now and Post-Pandemic

    Voices for Medtech: AdvaMed and MDMA Leaders Share Thoughts

    Digitize Your QMS via an Enterprise Cloud Platform
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Top News
    Iterative Scopes Announces IBD-Focused Scientific Advisory Board

    Vicarious Surgical, D8 Holdings Corp. Combine Operations in $1.1 Billion Deal

    FDA Grants De Novo Clearance to Medtronic’s GI Genius Model

    Acutus Medical Receives FDA Clearance of AcQCross

    Thermo Fisher Scientific to Acquire PPD for $17.4 Billion
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    Transporting Treatment: An Examination of Tubing Technologies

    Outward Appearance: Reviewing Surface Treatment Options

    Face to (Virtual) Face: Telemedicine Now and Post-Pandemic

    Voices for Medtech: AdvaMed and MDMA Leaders Share Thoughts

    Digitize Your QMS via an Enterprise Cloud Platform
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    Home Is Where the Heart (Valve) Is

    CGM: Digital Health Meets a Very Large Opportunity

    Biomechanical Engineer, Heal Thyself

    Optimizing MIM in Medical Device Manufacturing

    PPE and Diagnostics: Sourcing Domestically and Speeding Time to Market
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    Trademark Plastics Inc.

    Medicoil

    Forefront Medical Technology

    Creganna Medical, part of TE Connectivity

    Unicep
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    Fiber Optics Introducing New Cleanliness Requirements for Medical Electronics

    EMS Providers Valued for Product Customization, Medical Certification Expertise

    Three Future Trends and Opportunities in Quality Assurance

    Adopting a Data-Driven Quality Model

    Digital Transformation for Quality and Manufacturing
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    Unicep

    Creganna Medical, part of TE Connectivity

    Spectrum Plastics Group

    Medbio LLC

    Concise Engineering
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • Podcasts
    • Resources
    • eBook
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Columns

    Facts to Ensure MDR Success

    Even with the delay of the European Union’s MDR deadline until May 26, 2021, the race to reach compliance is still on for medical device manufacturers.

    Facts to Ensure MDR Success
    MDR readiness is a challenge and it feels like there is always more to learn, especially with the impact of COVID-19 changing the world by the minute. Image courtesy of WuXi AppTec.
    Related CONTENT
    • Quality & Regulatory Solutions for the FDA Regulated Industries
    • Four Ways Remote Freelance Experts Can Help Medtech
    • FDA Clears Ava Fertility Tracking Wearable Device
    • 4 Trends Driving Medical Manufacturing in 2021
    • FDA Clears Wearable Electrocardiogram Sensor
    Sherry Parker, Ph.D. and Bob Pryzgoda, Ph.D.09.01.20
    Even with the delay of the European Union’s Medical Device Regulation (MDR) deadline until May 26, 2021, the race to reach compliance is still on for medical device manufacturers. The preparation and implementation processes are still extremely rigorous and time-consuming, and COVID-19 has caused additional strains for Notified Bodies (NB).

    Manufacturers need to prepare to navigate these conditions efficiently while readying devices for submission, leaving no room for error. They have to know all the minor ins and outs of the MDR to ensure submissions are compliant and completed on time. There are often overlooked facts to consider when preparing an MDR submission that can help manufacturers minimize risk and pass their submissions with flying colors.

    Compliant Data vs. State-of-the-Art
    While it is required for companies to submit complete data packages for all devices aiming to remain on the EU market, additional testing may not be necessary to satisfy the expectation that all device evaluations meet current standards as required under the MDR. Regulators will accept tests and evaluations that do not meet current standards if any gaps identified in the tests or evaluations can be justified as meeting MDR requirements. Manufacturers have until May 27, 2024, to comply with this requirement.

    The legal formalities of accepting new or revised standards in the EU can be time-consuming and cumbersome. Standards that are legally accepted by all EU countries are referred to as harmonized standards. Device evaluation requirements must meet the expectations set by harmonized standards. Still, regulatory reviewers may expect testing to meet ISO-approved standards that are not yet harmonized to be used in the evaluations because these standards are considered state-of-the-art. The challenge for manufacturers is balancing when to use data that only comply with current harmonized standards and when it is worth the extra time to generate data that will meet the state-of-the-art unharmonized ISO standards.

    Broadly, there have not been numerous changes to biocompatibility standards and most of the testing methods are still sound. Some manufacturers can satisfy MDR testing requirements without having to do any additional biocompatibility testing. One area for consideration during submission preparation is the expectation to limit the use of in vivo testing. Unnecessary in vivo testing may place submissions in a negative light for EU regulators. If in vivo testing is necessary for specific devices, it may be beneficial to look into whether past data is still compliant to avoid the need for further testing.

    The most significant testing changes are associated with chemical characterization. ISO 10993-18:2020, while not harmonized, now represents the state-of-the-art for chemical analysis. The previous harmonized version of ISO 10993-18 provided limited guidance. However, it is unlikely that past data—possibly even testing from 2019 to prepare for the MDR—comes close to offering the same in-depth quality of data generation and evaluation as the 2020 version. New updates to the standard include several definitions and annexes to lend consistency to industry-wide chemical characterization. Although ISO 10993-18 added a significant level of detail, it does not offer clear test methods for conducting chemical characterization, which is why it will be essential to work with a lab testing partner to provide state-of-the-art analysis.

    Furthermore, ISO 10993-17 is in development, with the current goal of publication going into effect in 2021. Part 17 will require a thorough and defendable toxicological risk assessment. Some regulators are already expecting some of the requirements in this revised standard to be met. Once this standard is ISO approved, any risk assessment using the current part 17 standard will likely need to be revised. It is worth investing in preparing that risk assessment now since the implementation date is fast approaching. In these assessments, manufacturers must make expert judgment calls and defend them to regulators. Work with a lab testing partner to get comfortable performing and defending risk assessments now for long-term success.

    Rigorous Testing for Short-Term Devices
    Under the Medical Device Directive (MDD), the contact duration of a device played a critical role in determining testing requirements. The testing results for transient exposure devices would not face the same level of scrutiny for carcinogenic, mutagenic, or toxic to reproduction substances (CRM substances) as long-term duration devices. However, under the MDR, any invasive device, including those with less than 24 hours of patient contact, will require knowledge of any CMRs present in device components at a concentration equal to or greater than 0.1 percent. If this information is not available, NBs will likely direct manufacturers back to chemistry testing to find answers. If CMRs are present in device components, a risk assessment and justification for continued use of the material will be required.

    Toxicologists and regulatory bodies are consistently updating the CRM substance list, so it is advantageous to work with a lab that can help manufacturers stay informed and updated on the chemicals that cause red flags during submission review.

    What Supply Chain Disruptions Mean for New Materials
    Due to supply chain strains caused by COVID-19, acquiring raw materials promptly and in the correct quantity can be challenging. Manufacturers are now reconsidering their device materials and go-to suppliers. Some are even discovering their back-up material choice is no longer an option, forcing them to go further down their list of preferences.

    More suppliers are facing pressure to undergo chemistry testing for materials in new applications to ensure they are sufficient quality or considered medical grade. Using a supplier that provides detailed information on their materials is preferable, especially with the pressure to recognize the presence of CMR substances in a greater pool of devices. The same testing requirements for CMR substances must be in place for alternative suppliers, leading to more chemical testing to comply with the MDR.

    Biocompatibility Specialists in Short Supply
    The demand for biocompatibility specialists is high, which may make finding qualified experts difficult. The medical device industry is transitioning to the MDR requirements and the increased work to achieve this is putting a significant amount of stress on the labor market. Manufacturers must employ biocompatibility specialists for both normal operations and MDR operations, meaning there is limited capacity both internally and with contracted partners. As a result, some manufacturers have taken to pushing quality engineers and regulatory experts into roles to which they are not adept.

    The best solution is to plan accordingly and identify where additional support could be beneficial early in project development. The biggest mistake a manufacturer can make is not planning appropriately and consequently scrambling to find resources at the last minute. Start testing early and make the necessary investments to complete a comprehensive device assessment that complies with MDR requirements.

    Developing a Submission Plan
    Limits to capacity are not only affecting internal manufacturing teams but also outsourced testing partners, since more device manufacturers are turning to them for testing and guidance. Some contract research organizations have expanded their bandwidth for MDR preparation. Still, there are no guarantees they will be able to meet everyone’s needs against the compliance timelines. The longer companies wait to communicate their submission strategy and preparation timeline with testing labs, the longer it will take to work their way to the front of the line.

    The best strategy for getting on a testing partner’s schedule is prepare a plan aligned to the MDR regulatory submission timeline. Labs are more likely to accommodate those who have a plan and can prioritize their portfolios. Without a plan, companies risk having insufficient data that could cause a significant setback.

    Less Room for Error
    There are only 15 MDR approved NBs, a substantial decrease compared to the number NBs under the MDD. And once the MDR approves a NB, it will no longer accept submissions under the MDD. On top of that, COVID-19 has slowed down the entire review process. Even with the MDR application extension, the transition is still moving at a slow pace. Currently, NBs are focusing on the influx of critical work needed for Personal Protective Equipment to keep enough of these critical devices on the market to address the pandemic.

    With a limited number of NBs stretched to capacity, there is a limited amount of time to review each submission and provide feedback. There is no guarantee they’ll provide in-depth details about submission errors if something is incomplete. Instead, they may require more information and send companies to the back of the line for review. NBs will likely show a preference for manufacturers that provide detailed information, including labeling for CMR substances. Additionally, working with a third-party testing partner can also help build credibility in a reviewer’s eye.

    MDR readiness is a challenge and it feels like there is always more to learn, especially with the impact of COVID-19 changing the world by the minute. It is best to approach the process with the intention to over-prepare. By investing upfront in proper chemical characterization, skilled labor, supply chain alternative, and a knowledgeable testing partner, manufacturers can avoid lost time on the market and high costs later on. 


    Dr. Sherry Parker has over 20 years of toxicology and medical device experience, and is an expert in analytical, pharmacological, and toxicological evaluations of medical devices and combination products. After receiving her Ph.D. in molecular and cellular pharmacology from the University of Miami, Dr. Parker worked as a toxicologist for the U.S. EPA, RTI International, OrbusNeich Medical, and Fresenius Medical Care. In her current position at WuXi AppTec, Dr. Parker guides manufacturers on global regulatory and technical requirements and testing program design. In May 2019, Dr. Parker was appointed to a three-year term as co-chair of the Advancing Safety in Health Technology / Biological Evaluation Committee.

    For 15 years, Dr. Robert T. Przygoda served as both the manager of the Genetic Toxicology Group and the study director for Genetic Toxicity Tests at Exxon Biomedical Sciences. He chaired the American Industrial Health Council’s Mutagenicity Sub-Committee from 1992-1994. Dr. Przygoda was elected to the Board of Directors from 1996 - 2000. From 1999 – 2000 he was the president of the Genetic Toxicology Association. In 1999, Dr. Przygoda joined Ethicon Endo-Surgery, a Johnson & Johnson Company, where he assisted in the development of the medical device biocompatibility evaluation program. Dr. Przygoda received his Ph.D. in microbiology and molecular genetics from Rutgers University and the UMDNJ.
    Suggested For You
    Quality & Regulatory Solutions for the FDA Regulated Industries Quality & Regulatory Solutions for the FDA Regulated Industries
    Four Ways Remote Freelance Experts Can Help Medtech Four Ways Remote Freelance Experts Can Help Medtech
    FDA Clears Ava Fertility Tracking Wearable Device FDA Clears Ava Fertility Tracking Wearable Device
    4 Trends Driving Medical Manufacturing in 2021 4 Trends Driving Medical Manufacturing in 2021
    FDA Clears Wearable Electrocardiogram Sensor FDA Clears Wearable Electrocardiogram Sensor
    A Blueprint for Reducing Medtech Industry A Blueprint for Reducing Medtech Industry's Carbon Footprint
    Greenlight Guru and Nelson Labs Partner Greenlight Guru and Nelson Labs Partner
    Expert Roundup: Achieving Success in the 2021 Medical Device Landscape Expert Roundup: Achieving Success in the 2021 Medical Device Landscape
    The Printed World: Additive Manufacturing in Medtech The Printed World: Additive Manufacturing in Medtech
    FDA Approves Boston Scientific FDA Approves Boston Scientific's Ranger Drug-Coated Balloon
    FDA OKs CEFALY DUAL Migraine Treatment for Use Without Prescription FDA OKs CEFALY DUAL Migraine Treatment for Use Without Prescription
    Abbott Shares ID NOW COVID-19 Interim Clinical Study Results Abbott Shares ID NOW COVID-19 Interim Clinical Study Results
    Device Success Contingent Upon Flexible Circuit Design Device Success Contingent Upon Flexible Circuit Design
    From the Experts: Best Practices to Ensure Device Success From the Experts: Best Practices to Ensure Device Success
    MDR Delay Official; Industry Urges Push Back of IVDR MDR Delay Official; Industry Urges Push Back of IVDR

    Related Columns

    • Cardiovascular | Surgical
      Home Is Where the Heart (Valve) Is

      Home Is Where the Heart (Valve) Is

      Artificial heart valve makers reached a number of milestones despite the pandemic’s global squeeze.
      Sam Brusco, Associate Editor 04.01.21

    • Chronic Disease | Digital Health | Patient Monitoring
      CGM: Digital Health Meets a Very Large Opportunity

      CGM: Digital Health Meets a Very Large Opportunity

      Continuous glucose monitors (CGMs) are one of the most formidable diabetes management tools to be developed in decades.
      Maria Shepherd, President and Founder, Medi-Vantage 04.01.21

    • Surgical
      Biomechanical Engineer, Heal Thyself

      Biomechanical Engineer, Heal Thyself

      Choosing a treatment option for spinal disorders can be tricky with extensive knowledge of the industry.
      Dawn A. Lissy, Founder & President, Empirical 04.01.21


    • Molding | Surgical
      Optimizing MIM in Medical Device Manufacturing

      Optimizing MIM in Medical Device Manufacturing

      Metal injection molding (MIM) is a good choice for producing medium- to high-volume medtech parts.
      Steve Santoro, Executive Vice President, MICRO 04.01.21

    • Diagnostics
      PPE and Diagnostics: Sourcing Domestically and Speeding Time to Market

      PPE and Diagnostics: Sourcing Domestically and Speeding Time to Market

      With smart onshoring strategies, the medical device industry can collaborate to fix supply chain issues.
      Claudio Hanna and Ralph Tricomi , Web Industries 04.01.21

    • Testing
      The Evolution of Chemical Characterization for Medical Devices

      The Evolution of Chemical Characterization for Medical Devices

      Evaluation of biological safety of devices is experiencing some of the most significant changes in history.
      Sandi Schaible, Senior Director, Analytical Chemistry and Regulatory Toxicology, WuXi AppTec Medical Device Testing 04.01.21


    • Digital Health
      How Digital Health Fits into the Medtech Mold

      How Digital Health Fits into the Medtech Mold

      Healthcare will need to adopt digital technologies that streamline and enhance connectivity.
      Florence Joffroy-Black and Dave Sheppard, MedWorld Advisors 04.01.21

    • Global Supply Chain Wisdom from Coronavirus-Colored Lenses

      Global Supply Chain Wisdom from Coronavirus-Colored Lenses

      There are precious pearls of wisdom from this past year that will come in handy during the next “crisis.”
      Chris Oleksy, Founder and CEO, Oleksy Enterprises and Co-Founder Next Life Medical; CEO, Emergent Respiratory 04.01.21

    • Four Considerations When Selling to a Private Equity Fund

      Four Considerations When Selling to a Private Equity Fund

      A private equity partner can help medtech firms expand into new markets and serve existing clients better.
      Bill Hadler and Anisa Mohanty, McDermott Will & Emery 04.01.21


    • Software & IT
      Cybersecurity Compromises, Courtesy of COVID-19

      Cybersecurity Compromises, Courtesy of COVID-19

      As the healthcare industry focused its energies last year on battling SARS-CoV-2, cybercriminals used the distraction to their advantage.
      Michael Barbella, Managing Editor 03.04.21

    • A Look at the Actual Device Costs for Hospitals

      A Look at the Actual Device Costs for Hospitals

      According to a 2018 clinical journal article, U.S. hospitals spent approximately $200 billion on medical devices.
      Maria Shepherd, President and Founder, Medi-Vantage 03.04.21

    • Show Time: Here’s What a Year of No Tradeshows Meant for Small Businesses

      Show Time: Here’s What a Year of No Tradeshows Meant for Small Businesses

      For small businesses, trade shows are a critical part of developing new business as well as maintaining contacts.
      Dawn A. Lissy, Founder & President, Empirical 03.04.21


    • FDA Making Progress With Technology and Data Action Plans

      FDA Making Progress With Technology and Data Action Plans

      There is an urgent need to get advanced technologies into the healthcare ecosystem, but all products must first get regulatory approval.
      Alan Rencher, Vice President, Engineering, MasterControl 03.04.21

    • What’s Hot Now in Medtech M&A

      What’s Hot Now in Medtech M&A

      Every M&A cycle in the life sciences/medtech sector fosters exciting deals that interestingly impact the industry in both the short and long term.
      Florence Joffroy-Black and Dave Sheppard, MedWorld Advisors 03.04.21

    • Software & IT
      Three Ways to Fast-Track the Total Product Lifecycle

      Three Ways to Fast-Track the Total Product Lifecycle

      Here are three ways leaders including Alcon, Baxter Healthcare, Boston Scientific, Epredia, and Illumina are driving innovation in medtech.
      Seth Goldenberg, Ph.D., Vice President, MedTech, Veeva Systems 03.04.21


    Trending
    • 7 Considerations For Designing Medical Device Mechanisms
    • Portable, Home-Use Device Quickly Measures Inflammation Levels
    • Thermo Fisher Scientific To Acquire PPD For $17.4 Billion
    • Katena Acquires Ophthalmic Surgical Instrument Maker ASICO
    • Harnessing Critical Health Data With Wearable Technology
    Breaking News
    • Iterative Scopes Announces IBD-Focused Scientific Advisory Board
    • Vicarious Surgical, D8 Holdings Corp. Combine Operations in $1.1 Billion Deal
    • FDA Grants De Novo Clearance to Medtronic’s GI Genius Model
    • Acutus Medical Receives FDA Clearance of AcQCross
    • Thermo Fisher Scientific to Acquire PPD for $17.4 Billion
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Transporting Treatment: An Examination of Tubing Technologies
    • Face to (Virtual) Face: Telemedicine Now and Post-Pandemic
    • Outward Appearance: Reviewing Surface Treatment Options
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    AstaReal Astaxanthin Ingredient Receives U.S. Patent Approval
    Study on Kemin’s DailyZz Botanical Blend Uncovers Sleep Quality, Next-Day Performance Benefits
    FDA’s Dr. Cara Welch Opening Speaker at the 9th AHPA Botanical Congress
    Coatings World

    Latest Breaking News From Coatings World

    Jebsen & Jessen, Innospec Sign Distribution Agreement
    IGL Coatings Announces Partnership in Finland
    Axalta Schedules 1Q 2021 Earnings Conference Call
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Iterative Scopes Announces IBD-Focused Scientific Advisory Board
    Vicarious Surgical, D8 Holdings Corp. Combine Operations in $1.1 Billion Deal
    FDA Grants De Novo Clearance to Medtronic’s GI Genius Model
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Bristol Myers Squibb Expands at Cambridge Crossing
    Amgen Completes Five Prime Acquisition
    Sartorius Expands in the UK
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Former L’Oréal Exec Joins Glossier
    Lancôme Reveals New Global Sustainability Program
    First-Ever Skincare Line Focuses on Iron To Prevent Aging
    Happi

    Latest Breaking News From Happi

    Fragrance Creators Association Celebrates P&G Executive
    What You're Reading on Happi.com
    Former L’Oréal Exec Joins Glossier
    Ink World

    Latest Breaking News From Ink World

    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    SE-DA Invests in Kornit Presto S
    Acrylic Resins Market Worth $21.9 Billion by 2025: MarketsandMarkets
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    TLMI reveals Eugene Singer Award winners at Virtual Spring Summit
    Monadnock Paper Mills joins SGP
    ACTEGA helps converter reach sustainability goals
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Albaad to Add Natural-Based Line in Israel
    First Quality to Discontinue Tampon Operations
    Jessup Installs New Era Coating and Laminating Line
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    BioMagnetic Sciences Names President and CEO
    Mainstay Medical Launches ReActiv8 in Australia
    Biogennix Rolls Out Agilon Strip Bone Graft
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Virtual ASMC 2021 Spotlights Advanced Semiconductor Manufacturing Excellence
    LG Display Cuts Down CO2-eq Emissions by 3 Million Tons in 2020
    European Commission's Innovation Radar Acknowledges 3 ARMOR Innovations

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login